MMF Immunosuppression — Competitive Intelligence Brief

MMF Immunosuppression (MMF Immunosuppression) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant. Area: Immunology.

phase 2 Immunosuppressant IMPDH Immunology Small molecule

Target snapshot

MMF Immunosuppression (MMF Immunosuppression) — Wondercel Biotech (ShenZhen). Inhibits inosine monophosphate dehydrogenase (IMPDH)

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MMF Immunosuppression TARGET	MMF Immunosuppression	Wondercel Biotech (ShenZhen)	phase 2	Immunosuppressant	IMPDH
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
sirolimus, mycophenolat mofetil, fluvastatin	sirolimus, mycophenolat mofetil, fluvastatin	University Hospital Schleswig-Holstein	marketed	Immunosuppressive combination therapy with statin	mTOR, IMPDH, HMG-CoA reductase
Copegus (ribavirin)	Copegus (ribavirin)	Hoffmann-La Roche	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
CsA+MMF+CS	CsA+MMF+CS	Pfizer	marketed	Immunosuppressive combination therapy	Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS)
Sirolimus+MMF or MPS or AZA+Steroid	Sirolimus+MMF or MPS or AZA+Steroid	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Immunosuppressive combination therapy	mTOR (sirolimus); IMPDH (MMF/MPS); purine synthesis (AZA); glucocorticoid receptor (steroid)
Placebo to Mycophenolate mofetil	Placebo to Mycophenolate mofetil	Hoffmann-La Roche	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant class)

1. Assistance Publique Hopitaux De Marseille · 1 drug in this class
2. Centre Hospitalier Universitaire, Amiens · 1 drug in this class
3. Hospices Civils de Lyon · 1 drug in this class
4. I.M. Sechenov First Moscow State Medical University · 1 drug in this class
5. Kenya Medical Research Institute · 1 drug in this class
6. Memorial Sloan Kettering Cancer Center · 1 drug in this class
7. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. RWTH Aachen University · 1 drug in this class
10. Samsung Medical Center · 1 drug in this class